Skip to main content
Fig. 2 | EJNMMI Research

Fig. 2

From: Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine

Fig. 2

Comparative biodistributions (%IA/g ± SD) after i.v. administration of 213Bi-DOTATATE vs. 111In-DOTATATE (0.3 nmol peptide, n = 3/cohort) at 10 and 60 min p.i. in AR42J tumor-bearing mice. The uptake was expressed as percentage of injected activity per gram of tissue (%IA/g)

Back to article page